Scarica l'app Stockscreener
0.97
2.51%
-0.025
Dopo l'orario di chiusura:
1.03
0.06
+6.19%
Precedente Chiudi:
$0.995
Aprire:
$1
Volume 24 ore:
66,507
Relative Volume:
0.42
Capitalizzazione di mercato:
$15.60M
Reddito:
-
Utile/perdita netta:
$-11.90M
Rapporto P/E:
-0.00471
EPS:
-206.0125
Flusso di cassa netto:
$-12.75M
1 W Prestazione:
+5.21%
1M Prestazione:
-19.17%
6M Prestazione:
-38.99%
1 anno Prestazione:
+19.46%
Intervallo 1D:
$0.97
$1.02
Intervallo di 1 settimana:
$0.90
$1.0389
Portata 52W:
$0.6138
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Nome
Allarity Therapeutics Inc
Settore
Industria
Telefono
401-426-4664
Indirizzo
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
0.97 | 16.00M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Iniziato | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie
Allarity Therapeutics doses first patients in VA-funded small cell lung cancer trial - Mugglehead Investment Magazine
Why analysts upgrade Allarity Therapeutics Inc. stockRate Hike & Real-Time Buy Zone Alerts - mfd.ru
Allarity Therapeutics doses first patients in VA-funded Phase 2 SCLC trial - TradingView
Allarity Therapeutics Doses First Patients in Phase 2 Lung Cancer Trial - marketscreener.com
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - The Manila Times
Allarity Therapeutics Initiates VA-Funded Phase 2 Trial of Stenoparib and Temozolomide for Relapsed Small Cell Lung Cancer - Quiver Quantitative
VA lung cancer trial tests new drug combo for patients with few options - Stock Titan
What is Allarity Therapeutics Inc. s 5 year growth outlook2025 Key Lessons & Detailed Earnings Play Strategies - mfd.ru
Why Allarity Therapeutics Inc. stock remains on buy listsWeekly Profit Report & Real-Time Volume Analysis - mfd.ru
Biotechnology company Allarity Therapeutics Inc recently filed documents with the U.S. Securities and Exchange Commission, disclosing that its selling shareholders plan to resell 255,103 shares of the company’s common stock. - Bitget
Value Recap: What is the next catalyst for Allarity Therapeutics IncTrade Risk Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
What is the target price for Portman Ridge Finance Corporation stockInsider Selling & Real-Time Volume Spike Alerts - baoquankhu1.vn
Will Allarity Therapeutics Inc. stock recover after earningsJuly 2025 Snapshot & Risk Controlled Stock Alerts - mfd.ru
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Aug Setups: Will Wrap Technologies Inc face regulatory challengesJuly 2025 Weekly Recap & Entry Point Confirmation Signals - baoquankhu1.vn
Allarity Therapeutics Opens Enrollment for Phase 2 Trial in Lung Cancer - TradingView
Allarity begins phase 2 trial of stenoparib combination for lung cancer - Investing.com Nigeria
Allarity Therapeutics and US Veterans Administration open enrollment for mid-stage trial of stenoparib with temozolomide in relapsed small cell lung cancer - marketscreener.com
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - ChartMill
Allarity Therapeutics And US Veteran’S Administration Open Enrollment For Mid-Stage Trial Of Stenoparib With Temozolomide In Relapsed Small Cell Lung Cancer - TradingView
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Can Allarity Therapeutics Inc. keep up with sector leadersJuly 2025 Weekly Recap & Intraday High Probability Alerts - baoquankhu1.vn
Published on: 2026-02-02 00:08:12 - baoquankhu1.vn
Published on: 2026-02-09 17:34:13 - baoquankhu1.vn
Can Allarity Therapeutics Inc. disrupt its industryChart Signals & Reliable Breakout Forecasts - mfd.ru
Published on: 2026-01-29 19:48:00 - mfd.ru
Allarity Therapeutics Secures Flexible Equity Financing Facility - TipRanks
Allarity Therapeutics Signs Common Stock Purchase Agreement With Tumim Stone Capital - TradingView
Activity Recap: Will Advanced Flower Capital Inc benefit from rising consumer demand2025 Performance Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Can Allarity Therapeutics Inc disrupt its industryMarket Activity Report & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Declines By 17.1% - Defense World
Aug EndMonth: Is Allarity Therapeutics Inc backed by strong institutional buying2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Can Allarity Therapeutics Inc expand its profit margins2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Published on: 2026-01-16 10:01:32 - baoquankhu1.vn
Published on: 2026-01-16 08:05:07 - baoquankhu1.vn
Meme Stocks: Is Yuanbao Inc Depositary Receipt stock influenced by commodity pricesJuly 2025 Gainers & Reliable Price Action Trade Plans - baoquankhu1.vn
Market Outlook: What valuation multiples suggest for Allarity Therapeutics Inc stockJuly 2025 WrapUp & Weekly Stock Breakout Alerts - Bộ Nội Vụ
EV Market: Can Allarity Therapeutics Inc keep up with sector leadersProfit Target & Weekly Return Optimization Alerts - baoquankhu1.vn
Loss Report: Can Allarity Therapeutics Inc stock maintain growth trajectoryShare Buyback & Stepwise Trade Execution Plans - Bộ Nội Vụ
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Cardio Diagnostics (NASDAQ:CDIO) - Defense World
Market Wrap: What dividend safety score for Allarity Therapeutics Inc stockQuarterly Performance Summary & Technical Confirmation Alerts - Bộ Nội Vụ
What catalysts could drive Allarity Therapeutics Inc. stock higherJuly 2025 Weekly Recap & Weekly High Momentum Picks - Улправда
Allarity Therapeutics, Inc.Common stock (NQ: ALLR - FinancialContent
How Allarity Therapeutics Inc. stock benefits from tech adoptionMarket Risk Report & Growth Oriented Trade Recommendations - ulpravda.ru
How strong is Allarity Therapeutics Inc. stock balance sheetPrice Support Zones & Free Tap Rapid Wealth - Улправда
News | postregister.comAllarity Therapeutics, Inc.Common stock (Nasdaq:ALLR) Price Chart - FinancialContent
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus
Is Allarity Therapeutics Inc. stock a buy before product launches2026 world cup usa national team qualification young talents high defensive line winner prediction guide - ulpravda.ru
Allarity CEO says 2026 represents an ‘inflection point’ - Yahoo Finance
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders - GlobeNewswire
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 21.9% in December - Defense World
Allarity Therapeutics Inc Azioni (ALLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):